Clinical Trial Detail

NCT ID NCT04262388
Title A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

pancreatic ductal adenocarcinoma

lung non-small cell carcinoma

head and neck squamous cell carcinoma

Therapies

Durvalumab + Oleclumab

Age Groups: adult senior

No variant requirements are available.